C. Yılmaz

Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients.

R. Durusoy, B. Zengel, Ö. Özdemir, 2022, European journal of breast health.

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

O. Avci, Mustafa YILMAZ, S. Paydaş, 2022, Anti-cancer drugs.

Are Hormonal Agents Better Than Chemo İn Metastati̇c Castrati̇on Resistant Prostate Cancer?

A. Erdoğan, F. Ekinci, G. Bulut, 2021, Turkish Journal of Oncology.

Comparison of progressed and unresponsive patients with responsive patients at ınterim assessment during breast cancer neoadjuvant chemotherapy

Ö. Özdemir, C. Yılmaz, Özlem Özdemir, 2022, Ege Tıp Dergisi.

The Importance of the Pathological Perspective in the Management of the Invasive Lobular Carcinoma

E. İlhan, H. Mollamehmetoğlu, A. Uslu, 2022, The breast journal.

Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances

C. Yılmaz, D. Çavdar, 2022, Current oncology.

Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?

A. Erdoğan, F. Ekinci, G. Bulut, 2021, Journal of Gastrointestinal Cancer.

Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab.

A. Erdoğan, S. Barutça, F. Ekinci, 2022, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.